Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases

Background: Management options for pancreatic neuroendocrine tumors (pNETs) metastatic to the liver include surgical, ablative, cytotoxic, and radioisotope approaches. One potential local treatment option includes selective internal radiotherapy utilizing yttrium-90 ( 90 Y) microspheres. 90 Y has also been used in the treatment of hepatocellular carcinoma and tumors metastatic to the liver. It appears to be well tolerated; however, there is no randomized controlled trial reporting long-term toxicities. Previous retrospective reports have described biliary damage as a potential complication of therapy with 90 Y and chemoembolization; however, the long-term sequelae of 90 Y treatment are poorly understood. Case Presentation: We present the case of a 65-year-old Caucasian woman who suffered biliary damage following 90 Y administration for metastatic pNETs and subsequently developed cirrhosis. Given the timeline of her various treatments and the lack of any other identifiable etiology for her cirrhosis, we believe this to be a potential long-term complication of 90 Y therapy. Conclusion: This case provides pathologic confirmation of cirrhosis as a potential long-term sequela of 90 Y treatment. This long-term risk needs to be considered when sequencing therapy for patients with neuroendocrine tumors who have a good prognosis. There are now several other systemic and ablative treatment options available to these patients, and long-term complications must be considered during treatment. © 2016 The Author(s) Published by S. Karger AG, Basel D ow nl oa de d by : 54 .7 0. 40 .1 1 11 /2 0/ 20 17 1 1: 06 :3 1 A M 77 Case Rep Oncol 2016;9:76–82 DOI: 10.1159/000443985 © 2016 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro Loree et al.: Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases